



PRIOR AUTHORIZATION POLICY

POLICY: Inflammatory Conditions – Litfulo Prior Authorization Policy

- Litfulo™ (ritlecitinib capsules – Pfizer)

REVIEW DATE: 07/05/2023; selected revision: 07/26/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Litfulo, a kinase inhibitor, is indicated for the treatment of **severe alopecia areata** in patients \geq 12 years of age.¹ It inhibits the janus kinase 3 (JAK) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) pathways.

Guidelines

Although specific drugs are not mentioned, JAK inhibitors (JAKis) as a therapeutic class are addressed in an international expert opinion on treatments for alopecia areata (2020).² JAKis are identified among the therapies for treatment of extensive hair loss. First-line treatments for adults include topical and/or systemic corticosteroids. Steroid-sparing therapies to mitigate the risk associated with prolonged use of corticosteroids include cyclosporine, methotrexate, azathioprine, and JAKis. Based on the expert opinion, JAKis are considered the ideal option amongst systemic, steroid-sparing agents.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Litfulo. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Litfulo as well as the

monitoring required for adverse events and long-term efficacy, initial approval requires Litfulo to be prescribed by or in consultation with a physician who specializes in the condition being treated.

- **Litfulo™ (ritlecitinib capsules – Pfizer)**
is(are) covered as medically necessary when the following criteria is(are) met for fda-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indication

1. Alopecia Areata. Approve for the duration noted if the patient meets one of the following (A or B):

Note: Alopecia universalis and alopecia totalis are subtypes of alopecia areata.

A) Initial Therapy. Approve for 6 months if the patient meets all of the following (i, ii, iii, iv, and v):

i. Patient is \geq 12 years of age; AND

ii. Patient has a current episode of alopecia areata lasting for \geq 6 months; AND

iii. Patient has \geq 50% scalp hair loss; AND

iv. Patient has tried at least one of the following for alopecia areata (a or b):

a) Conventional systemic therapy; OR

Note: Examples of conventional systemic therapies include corticosteroids, methotrexate, and cyclosporine. An exception to the requirement for a trial of one conventional systemic agent can be made if the patient has already tried Olumiant (baricitinib tablet).

b) Topical corticosteroid; AND

v. The medication is prescribed by or in consultation with a dermatologist.

B) Patient is Currently Receiving Litfulo. Approve for 1 year if the patient meets all of the following (i, ii, iii, and iv):

i. Patient is \geq 12 years of age; AND

ii. Patient has been established on Litfulo for at least 6 months; AND

Note: A patient who has received $<$ 6 months of therapy or who is restarting therapy with the requested drug is reviewed under criterion A (Initial Therapy).

iii. Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Litfulo) in extent and density of scalp hair loss; AND

iv. According to the prescriber, the patient continues to require systemic therapy for treatment of alopecia areata.

Note: International consensus states that systemic treatment is best discontinued once complete regrowth has been achieved and maintained for 6 months or when regrowth is sufficient to be managed topically.

CONDITIONS NOT COVERED

- **Litfulo™ (ritlecitinib capsules – Pfizer)** is(are) considered experimental, investigational or unproven for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. Concurrent Use with an Oral or Topical Janus Kinase Inhibitor (JAKi).¹

Litfulo should not be administered in combination with another JAKi. Combination therapy is generally not recommended due to a potential for a higher rate of adverse effects and lack of evidence for additive efficacy.

Note: Examples include Olumiant (baricitinib tablets), Rinvoq (upadacitinib tablets), Xeljanz (tofacitinib tablets), and Opzelura (ruxolitinib cream).

2. Concurrent Use with a Biologic Immunomodulator. Litfulo is not recommended in combination with biologic immunomodulators.¹

Note: Examples include Adbry (tralokinumab-ldrm subcutaneous injection), Cinqair (reslizumab intravenous), Dupixent (dupilumab subcutaneous injection), Fasenra (benralizumab subcutaneous injection), Nucala (mepolizumab subcutaneous injection), Tezspire (tezepelumab-ekko subcutaneous injection), and Xolair (omalizumab subcutaneous injection).

3. Concurrent Use with Other Potent Immunosuppressants (e.g., cyclosporine, azathioprine).¹ Co-administration with other potent immunosuppressive drugs has the risk of added immunosuppression and has not been evaluated.

REFERENCES

1. Litfulo® capsules [prescribing information]. New York, NY: Pfizer; June 2023.
2. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. *J Am Acad Dermatol.* 2020;83:123-30.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy		07/05/2023
Selected Revision	Alopecia Areata: Listed alopecia universalis and alopecia totalis as subtypes of alopecia areata. Updated criteria for trial of systemic therapy to more specifically state conventional systemic therapy while allowing an exception if the patient has already tried Olumiant.	07/26/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna